Breadcrumb Home / Investors & Media / node Explore Investors & Media Explore Investors & Media Investor Overview Press Releases Archived Press Releases Events & Presentations Corporate Governance Committee Composition Management Team Board of Directors Financials & Filings SEC Filings Stock Information Historical Stock Lookup Investment Calculator Analyst Coverage Investor FAQs Contact IR or Media Srikripa Devarakonda, PhD Srikripa Devarakonda, PhD Truist Securities Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) Read more about Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) Scholar Rock Announces $205 Million Registered Direct Offering Read more about Scholar Rock Announces $205 Million Registered Direct Offering Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) Read more about Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference Read more about Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference Scholar Rock to Present at Jefferies Global Healthcare Conference 2022 Read more about Scholar Rock to Present at Jefferies Global Healthcare Conference 2022 Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities Read more about Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress Read more about Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress Andres Y. Maldonado, PhD Andres Y. Maldonado, PhD H.C. Wainwright Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting Read more about Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting Pagination First page « First Previous page ‹ Previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page Next › Last page Last » Subscribe to RSS Feeds Search
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) Read more about Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
Scholar Rock Announces $205 Million Registered Direct Offering Read more about Scholar Rock Announces $205 Million Registered Direct Offering
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) Read more about Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)
Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference Read more about Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference
Scholar Rock to Present at Jefferies Global Healthcare Conference 2022 Read more about Scholar Rock to Present at Jefferies Global Healthcare Conference 2022
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities Read more about Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress Read more about Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting Read more about Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting